Opdivo and Pleurisy - a phase IV clinical study of FDA data

Summary:

Pleurisy is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Yervoy, and have Non-small cell lung cancer recurrent.

The phase IV clinical study analyzes which people have Pleurisy when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Pleurisy?

Pleurisy (inflammation of the pleurae, which causes pain when breathing) is found to be associated with 819 drugs and 1,140 conditions by eHealthMe. Check the latest studies of Pleurisy.

On Jul, 08, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 36 people (0.06%) have Pleurisy.

Among these 36 people:

How long have people been on Opdivo when they have Pleurisy? *

What is the gender of people who have Pleurisy when taking Opdivo? *

female: 22.58 %
male: 77.42 %

What is the age of people who have Pleurisy when taking Opdivo? *

What are other drugs people take besides Opdivo? *

What are other side effects people have besides Pleurisy? *

Pleural Effusion (water on the lungs): 8 people, 22.22%
Pericarditis (inflammation of the pericardium): 6 people, 16.67%
Pericardial Effusion (fluid around the heart): 5 people, 13.89%
Uveitis (inflammation of the uvea): 3 people, 8.33%
Diarrhea: 3 people, 8.33%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 3 people, 8.33%
Fever: 3 people, 8.33%
Haemoglobin Decreased: 3 people, 8.33%
Thrombocytopenia (decrease of platelets in blood): 3 people, 8.33%
Myositis (inflammation of the muscles): 3 people, 8.33%

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 8 people, 22.22%
Pleural Mesothelioma Malignant (cancer of the pleura, or the membrane that lines the lungs): 7 people, 19.44%
Malignant Melanoma (skin cancer rises from melancytes): 3 people, 8.33%
Oesophageal Carcinoma (cancer tumour of oesophagus): 2 people, 5.56%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 2 people, 5.56%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 5.56%
Gastric Cancer (stomach cancer): 2 people, 5.56%
Colon Cancer: 2 people, 5.56%
Angiosarcoma (cancer of endothelial-type cells that line vessel walls): 2 people, 5.56%
Renal Cell Carcinoma (a kidney cancer): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Pleurisy?

- Check whether Pleurisy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Pleurisy treatments and more:

Pleurisy (9,090 reports)

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pleurisy:

Pleurisy (819 drugs)

Browse all the conditions that are associated with Pleurisy:

Pleurisy (1,140 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.